Evidence map›Paper›PMID 34107132›Full record

ReviewCancer science2021

Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.

Kentaro Matsuo, Kohei Taniguchi, Hiroki Hamamoto, Yosuke Inomata, Kazumasa Komura, Tomohito Tanaka, Sang-Woong Lee, Kazuhisa Uchiyama

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Targeting IDH-Mutant Glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Lung neuroendocrine neoplasms: recent progress and persistent challenges.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kentaro MatsuoDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kohei TaniguchiDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.ORCID https://orcid.org/0000-0003-0648-1370
Hiroki HamamotoDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Yosuke InomataDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kazumasa KomuraTranslational Research Program, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.ORCID https://orcid.org/0000-0003-4157-1929
Tomohito TanakaTranslational Research Program, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.ORCID https://orcid.org/0000-0003-4210-701X
Sang-Woong LeeDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Kazuhisa UchiyamaDepartment of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Osaka University of Pharmaceutical Sciences · JP

Funding

Japan Society for the Promotion of Science 18K16375Osaka Medical College (OMC) Internal Research Grant
6 · The paper itself

Abstract

Delta-like canonical Notch ligand 3 (DLL3) is a member of the Delta/Serrate/Lag2 (DSL) Notch receptor ligand family and plays a crucial role in Notch signaling, which influences various cellular processes including differentiation, proliferation, survival, and apoptosis. DLL3 is expressed throughout the presomitic mesoderm and is localized to the rostral somatic compartments; mutations in DLL3 induce skeletal abnormalities such as spondylocostal dysostosis. Recently, DLL3 has attracted interest as a novel molecular target due to its high expression in neuroendocrine carcinoma of the lung. Moreover, a DLL3-targeting Ab-drug conjugate, rovalpituzumab tesirine (ROVA-T), has been developed as a new treatment with proven antitumor activity. However, the development of ROVA-T was suspended because of shorter overall survival compared to topotecan, the second-line standard treatment. Thus, several studies on the mechanism and function of DLL3 in several malignancies are underway to find a new strategy for targeting DLL3. In this review, we discuss the roles of DLL3 in various malignancies and the future perspectives of DLL3-related research, especially as a therapeutic target.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzodiazepinonesClinical Trials as TopicFemaleGene Expression Regulation, NeoplasticHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzodiazepinonesDLL3 protein, humanImmunoconjugatesIntracellular Signaling Peptides and ProteinsMembrane Proteinsrovalpituzumab tesirineDLL3malignancyNotch signalingROVA-Ttherapeutic target

Identifiers

PMID34107132
PMCPMC8353941
OpenAlexW3172386340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.